The effects of dexmedetomidine infusion on the formation of reactive oxygen species during mesenteric ischemia-reperfusion injury in rats

Marmara Medical Journal

Volumn 20, Issue 3, 2007, Pages 154-160

  Inci, Feyza ^a   Doǧan, Varlik I ^a   Eti, Zeynep ^a   Deniz, Mustafa ^a   Göǧü, F Yilmaz ^a   Yaǧmur, Feyza ^a  

^a MARMARA UNIVERSITY   (Turkey)

Author keywords

2 adrenergic agonists; Dexmedetomidine; Ischemia reperfusion injury; Reactive oxygen species

Indexed keywords

DEXMEDETOMIDINE; GLUTATHIONE; LUCIGENIN; LUMINOL; MALONALDEHYDE; MYELOPEROXIDASE; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY LIGATION; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HISTOPATHOLOGY; ILEUM; ISCHEMIA; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; REPERFUSION INJURY; SHAM PROCEDURE; SUPERIOR MESENTERIC ARTERY;

EID: 43449129195     PISSN: 10191941     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 1985; 312: 159-163.
2. Stefanutti G, Vejchapipat P, Williams SR, Pierro A, Eaton S. Heart energy metabolism after intestinal ischaemia and reperfusion. J Pediatr Surg 2004; 39: 179-183.
3. Stoney RJ, Cunninghan CG. Acute mesenteric ischemia. Surgery 1993; 114: 489-490.
4. Grace PA. Ischaemia-reperfusion injury. Br J Surg 1994; 81: 637-647.
5. Kharbanda RK, Peters M, Walton B, et al. Ischemic preconditioning prevents endothelial injury and systemic activation during ischemia-reperfusion in humans in vivo. Circulation 2001; 103: 1624-1630.
6. Bhaskar L, Mathan MM, Balasubramanian KA. Oxygen free radical-induced damage during colonic ischemia/reperfusion in rats. Mol Cell Biochem 1995; 151 : 9-14.
7. Reichhalter R, Lillie C, Kobinger W. Effects of alinidine on survival and infarct size in rats with coronary artery occlusion. Eur J Pharmacol 1988; 157: 75-81.
8. Cai JJ, Morgan DA, Haynes WG, Martins JB, Lee HC. á2-adrenergic stimulation is protective against ischemia-reperfusion-induced ventricular arrhythmias in vivo. Am J Physiol Heart Circ Physiol 2002; 283: 2606-2611.
9. Yuan SZ, Runold M, Hagberg H, Bona E, Lagercrantz H. Hypoxic-ischaemic brain damage in immature rats: effects of adrenergic modulation. Eur J Paed Neurol 2001; 5: 29-35.
10. Virtanen R, Savola JM, Saano V, Nyman L. Characterization of the selectivity, specifity and potency of medetomidine as an á2-adrenoceptor agonist. Eur J Pharmacol 1988; 150: 9-14.
11. Kuhmonen J, Haapalinna A, Sivenius J. Effects of dexmedetomidine after transient and permanent occlusion of the middle cerebral artery in the rat. J Neural Transm 2001; 108: 261-271.
12. Jolkkonen J, Puurunen K, Koistinaho JR, et al. Neuroprotection by the á2-adrenoceptor agonist, dexmedetomidine, in rat focal cerebral ischemia. Eur J Pharmacol 1999; 372: 31-36.
13. Nacif-Coelho C, Correa-Saler C, Chang LL, Maze M. The hypnotic response to the á2-adrenoceptor agonist, dexmedetomidine in the locus coeruleus of the rat. Anesthesiology 1994; 81: 1527-1534.
14. Surprenant A, Horstman DA, Akbarali H, Limbird LE. A point mutation of the á2-adrenoceptor that blocks coupling to potassium but not calcium currents. Science 1992; 257: 977-980.
15. Vulliemoz Y, Shen H, Virag I. á2 Adrenoceptor agonists decrease cyclic guanosine 3′5′ monophosphate in the mouse brain. Anesthesiology 1996; 85: 544-550.
16. Talke P, Bickler PE. Effects of dexmedetomidine on hypoxia-evoked glutamate release and glutamate receptor activity in hippocampal slices. Anesthesiology 1996; 85: 551-557.
17. Matsumato M, Zornow MH, Rabin BC, Maze M. The á2-adrenergic agonist, dexmedetomidine, selectively attenuates ischemia-induced increases in striatal norepinephrine concentrations. Brain Res 1993; 627: 325-329.
18. Engelhard K, Werner C, Kaspar S, et al. Effect of the a2-agonist dexmedetomidine on cerebral neurotransmitter concentrations during cerebral ischemia in rats. Anesthesiology 2002; 96: 450-457.